InsiderTrades

Form 4 for HALO HALOZYME THERAPEUTICS, INC.

Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0001415889-23-002956 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-02-21 2023-02-16 HALO LaBarre Michael J. SVP, Chief TECHNICAL Off M - OptEx $0.00 +6,112 151.8K +4% $0
D 2023-02-21 2023-02-16 HALO LaBarre Michael J. SVP, Chief TECHNICAL Off S - Sale+OE $49.26 -2,878 148.9K -2% -$141.8K
DM 2023-02-21 2023-02-16 HALO LaBarre Michael J. SVP, Chief TECHNICAL Off A - Grant $0.00 +65.9K 48.8K New $0
D 2023-02-21 2023-02-16 HALO LaBarre Michael J. SVP, Chief TECHNICAL Off M - OptEx $0.00 -6,112 18.3K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-16 M A 6,112 $0.00 151,805 D — —
2 Common Common Stock 2023-02-16 S D 2,878 $49.26 148,927 D — — (F1) The reported disposition of 2,878 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
3 Derivative Restricted Stock Units 2023-02-16 A A 17,053 $0.00 17,053 D $0.00 · 2024-02-16 to — 17,053 Common Stock (F4) This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
4 Derivative Option to Purchase Common Stock 2023-02-16 A A 48,849 $0.00 48,849 D $49.26 · 2024-02-16 to 2033-02-16 48,849 Common Stock (F3) This option vests one-fourth on such date and then 1/48th monthly thereafter.
5 Derivative Restricted Stock Units 2023-02-16 M D 6,112 $0.00 18,336 D $0.00 · — to — 6,112 Common Stock (F2) This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.